Director, US Medical Affairs, Myeloma

Working with Us

Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it.

You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more:

The Medical Director, US Medical, Multiple Myeloma will report to the Senior Director, US Medical Multiple Myeloma Lead. He/she will be headquarter based, and will provide medical leadership for a novel CELMoD asset and support for the overall Multiple Myeloma portfolio of products. This individual will be involved in integrated strategic planning within Global Medical Affairs under the direction of the US Medical Multiple Myeloma lead and Global Multiple Myeloma disease lead as well as in close partnership with the US Commercialization organization, Clinical Research and Development, HEOR, Market Access, Translational Development, and Regulatory, and will lead the US Medical asset strategy supporting the US and Global Multiple Myeloma Disease Leads.

The Medical Director will provide key contribution for the asset medical strategy in the US, in alignment with overall US and World Wide Medical strategy, and will be responsible for execution of the medical plan for the asset in alignment with the overall MM medical strategy and under the direction of the Disease Leads. He/she will represent US Medical as asset lead in Multiple Myeloma with broad responsibilities and impact across the US business and overall Medical organization.

Execution of the strategy will be achieved through their therapeutic area expertise, launch excellence, execution of strategic tactics, and coordination with the rest of the US Medical team including functional leaders and the field-based team. He/she will work closely with the World Wide Medical Multiple Myeloma team to prepare for the US launch of new products, as appropriate.

• Oversee the US Medical Affairs strategic asset plan development and tactical execution, in coordination with the Global Medical Affairs and other cross-functional teams.
• Represent US Medical Affairs as a therapeutic area expert in both internal and external venues including the US and Global cross-functional teams, clinical sub-teams, and advisory boards / steering committees. Represent BMS at professional meetings, congresses, and local symposia.
• Lead launch readiness activities for key late stage asset(s) entering the market.
• Lead/support various Medical Affairs cross-functional working groups. Collaborate with Medical Affairs field colleagues to define, guide and execute therapeutic regional strategies and tactics with appropriate use of resources.
• Provide strategic input into the US publication, content development, scientific communications platform, and medical education strategy.
• Responsible for field medical leadership, including driving MSL asset strategy, integrated scientific engagement prioritization, and strategic medical insight collection.
• Provide high quality clinical input and review of congress abstracts, posters, presentation slides, manuscripts, educational materials, steering committee and advisory board meeting materials, medical information response documents, scientific educational grant requests, compassionate use requests, and patient advocacy grant requests among others.
• Track priority Medical Affairs tactics and performance to goals/budget.
• Support investigator-initiated trials, RWE planning, and lifecycle data strategy.

• Experiences in Multiple Myeloma…